Key Takeaways:
- We have developed technology that efficiently applies predictive ML models to combinatorial synthesis libraries (CSLs) at a rate of ~500 B compounds per second, per GPU, allowing us to exhaustively evaluate otherwise enumerable chemical space to identify diverse compounds that best fit multi-parameter optimization criteria.
- In practice, this gives chemists the opportunity to flexibly and iteratively explore enormous chemical space while receiving results, in the form of enumerated chemical structures, within seconds of their inquiry, fostering a genuine creative process that leads to higher chemical diversity and developability.
- We use this approach in conjunction with our next-generation extrapolative ML models, which has allowed us to discover high-quality, diverse, structurally-distinct binders for targets of interest; however, this approach can be extended to any advanced predictive model in order to exhaustively evaluate any CSL.
Advarra
Website: https://www.advarra.com/
Advarra breaks the silos that impede clinical research, aligning patients, sites, sponsors, and CROs in a connected ecosystem to accelerate trials. Advarra is number one in research review services, a leader in site and sponsor technology, and is trusted by the top 50 global biopharma sponsors, top 20 CROs, and 50,000 site investigators worldwide. Advarra solutions improve collaboration, transparency, and compliance to optimize study design and operations. With unmatched trial operations data, and an ongoing investment in AI innovation, Advarra continues to reimagine what’s possible in clinical research. For more information, visit advarra.com.
Rameez Chatni
Global Director, AI Solutions, Pharmaceutical & Life Sciences
Cloudera
Cloudera
Website: https://www.cloudera.com/
Cloudera is a hybrid platform for data, analytics, and AI. With 100x more data under management than other cloud-only vendors, Cloudera empowers global enterprises to transform data of all types, on any public or private cloud, into valuable, trusted insights. Our open data lakehouse delivers scalable and secure data management with portable cloud-native analytics, enabling customers to bring GenAI models to their data while maintaining privacy and ensuring responsible, reliable AI deployments. The world’s largest brands in financial services, insurance, media, manufacturing, and government rely on Cloudera to use their data to solve what once seemed impossible—today and in the future.
Frédéric Chabot
Head of Corporate Development
MindWalk
Frédéric Chabot is the Head of Corporate Development at MindWalk, focusing on M&A, strategic partnerships, and corporate initiatives. He began working with IPA in 2017, contributing in various roles before assuming his current position. With over 26 years of experience in finance and corporate strategy, he navigates biotech investments and market expansion.
Previously, he served as an International Liaison at Contact Financial, an advisory firm specializing in capital raising and investor relations for TSX and TSX-V listed companies. Over nine years, he worked on investor awareness programs and fundraising initiatives, supporting startups and early-stage companies.
MindWalk
Website: https://www.mindwalkai.com/
MindWalk is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT® technology and the LensAI™ platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.
Justin Byers
Founder and Chief Executive Officer
Axio BioPharma
Justin Byers is the Founder and Chief Executive Officer of Axio BioPharma, an AI biomanufacturing company revolutionizing how monoclonal antibodies are developed and produced. Based in Madison, Wisconsin, Axio launched in 2024 with a mission to accelerate and de-risk the development of recombinant proteins and monoclonal antibodies through AI-driven process design and U.S.-based manufacturing.
Under Justin’s leadership, Axio has pioneered a data-rich, machine learning–powered approach that reduces process development timelines from years to days unlocking faster, more cost-efficient pathways for biotech partners. He has steered the company’s rapid growth, from establishing its state-of-the-art facilities to securing strategic partnerships, including collaborations to advance next-generation drug delivery technologies.
With a background at the intersection of biomanufacturing, technology, and entrepreneurship, Justin brings a vision of scaling biologics development with speed, reliability, and accessibility. He is committed to building Axio into a trusted partner for innovators worldwide, combining scientific rigor with cutting-edge AI to bring life-changing therapies to patients faster.
Axio BioPharma
Website: https://www.axiobiopharma.com/
Axio BioPharma is an AI-driven biomanufacturing company revolutionizing how monoclonal antibodies are developed and produced. Headquartered in Madison, WI, Axio combines high-throughput production with proprietary machine learning to predict optimal scalable manufacturing processes in hours - not years. By accelerating development timelines and reducing costs, Axio enables biopharma innovators to bring life-saving therapies to market faster and more efficiently. With deep expertise in antibody manufacturing, protein purification, and bioinformatics, Axio supports a wide range of partners across research, diagnostics, and therapeutics with scalable, U.S.-based production and data-enhanced process design.